Sinaptica Therapeutics’ Presentation at the CTAD Conference
Sinaptica Therapeutics, Inc., a pioneering clinical-stage company in the field of neuromodulation, is preparing to present the results from a recent 52-week Phase 2 study focused on Mild-to-Moderate Alzheimer’s disease. This significant event will take place at the esteemed Clinical Trials on Alzheimer’s Disease (CTAD) conference, an important gathering for researchers and professionals dedicated to addressing Alzheimer’s challenges.
Key Presentation Details
The Sinaptica Therapeutics presentation at the conference will include crucial insights gained from their ongoing research and trials. The title of the oral presentation is Results of a 52-Week Phase II Trial of Repetitive TMS of the Default Mode Network in Mild to Moderate Alzheimer’s Disease. This session is scheduled for October 31 and will run from 11:25 a.m. to 12:00 p.m. CET, held in the Auditorium of the Madrid Marriott Auditorium Hotel and Conference Center.
Insights into Clinical Trials
Sinaptica’s research delves into innovative methods of treatment through the utilization of a specialized device known as the SinaptiStim System. This investigational system represents a breakthrough in non-invasive precision neuromodulation therapies. Tailored to the unique brain structures of each patient, treatments take place weekly in convenient 20-minute sessions. This careful calibration ensures targeted stimulation is delivered to the precuneus, a crucial part of the brain's Default Mode Network associated with memory and self-awareness.
The Future of Alzheimer’s Treatment
Alzheimer’s disease presents one of the most formidable challenges in healthcare today, influencing millions of lives worldwide. Recent research has highlighted the role of the Default Mode Network (DMN) in the pathology and progression of Alzheimer’s. By stimulating this network, the SinaptiStim System aims to enhance neuroplasticity, potentially helping the brain to fortify existing connections while forming new ones.
The FDA granted this pioneering technology the Breakthrough Device Designation in 2022, signaling its potential impact in the realm of neurodegenerative diseases. Sinaptica is gearing up for a pivotal randomized controlled clinical trial projected for 2025, in which treatments will be refined through advanced imaging techniques in conjunction with EEG to ensure precision.
Advancements in Clinical Research
During the CTAD conference, concurrent late-breaking poster presentations will further enrich the session. Data will be shared from a study titled Additional Analysis of a 52-Week Phase II Trial of Neuromodulation of the Default Mode Network. This research highlights the design of upcoming Phase 3 trials and their anticipated clinical significance.
A Closer Look at Sinaptica Therapeutics
Sinaptica Therapeutics is dedicated to transforming how neurodegenerative diseases are treated through its innovative neuromodulation therapies. The company aims to create a safe and effective non-invasive treatment system that can significantly mitigate the cognitive and functional decline seen in Alzheimer’s patients. With its roots in advanced neuroscience research, Sinaptica seeks to leverage a growing body of evidence to reverse or slow the progression of Alzheimer’s, ensuring a better quality of life for patients.
As part of their mission, Sinaptica continues to engage with the wider community and healthcare professionals to spread awareness of their innovative approaches. Their commitment to paving the way for personalized treatment options places them at the forefront of neuroscience research.
Frequently Asked Questions
What is the SinaptiStim System?
The SinaptiStim System is an investigational neuromodulation device developed by Sinaptica Therapeutics. It uses non-invasive techniques to provide personalized treatment for Alzheimer’s disease.
What role does the Default Mode Network play in Alzheimer's?
The Default Mode Network, including regions like the precuneus, is linked to critical cognitive functions such as memory. Its proper functioning may act as a protective factor against Alzheimer’s progression.
When and where will the presentation take place?
The presentation will occur on October 31 at the CTAD conference in Madrid from 11:25 a.m. to 12:00 p.m. CET.
What kind of outcomes will be measured in upcoming trials?
Upcoming trials will focus on measuring various biomarkers related to Alzheimer’s disease, such as beta amyloid levels and neural inflammation.
How can I learn more about Sinaptica Therapeutics?
For more information, visit the Sinaptica Therapeutics website, where you can find updates on their research and clinical trials.
